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ABSTRACT
Background: Parathyroid carcinoma (PC) is rare and diagnostically challenging. Reported outcomes are
rather poor and the incidence might be increasing.
Material and methods: We performed a nationwide study on all cases (n¼ 32) diagnosed in
2000–2011 in Finland, and compared clinical and histopathological characteristics and outcome to
atypical parathyroid (APA; n¼ 28) and parathyroid adenomas (PA; n¼ 72). The incidence in years
1955–1999 was compared to that in 2000–2013.
Results: Preoperatively, calcium and parathyroid hormone concentrations were higher in PC compared
to APA and PA (1.76, 1.56 and 1.44mmol/l, p< .001; and 989, 355 and 160lmol/l, p< .001, respect-
ively). Calcium was 1.77mmol/l for all PAs. Hospitalization (44% vs. 22% and 3%, respectively,
p¼ .01), renal (50% vs. 48% vs. 22%, respectively, p¼ .01) and bone (47% vs. 15% vs. 38%, respectively
p¼ .002) manifestations were more common. PC and APA tumors were larger than PA (p< .001).
Histopathological characteristics of PC compared to PA are increased mitotic activity (p¼ .001), chief
cells (p¼ .003), diffuse growth pattern (p< .001), higher Ki67 (p< .001) and negative parafibromin
(p< .001). One PC (1/18) and one APA (1/16) patient had a CDC73 mutation. After 6.7 (2–13.9) years of
follow-up, 9.4% of PC had residual, 21% recurrent disease and 12.5% died of disease. Overall mortality
did not differ between subgroups (p¼ .094). Recurrent PC was characterized by vascular invasion,
lymph node metastases, high mitotic activity, necrosis and negative parafibromin. Incidence increased
from 1.42 (range 0.52–2.14) to 7.14 (range 3.42–10.38)/10.000.000/years; (p< .001).
Conclusions: PC associates with severe primary hyperparathyroidism and must be suspected if cal-
cium 1.77mmol/l. The prevalence of CDC73 germline mutations in PC and APA in Finland is 6%.
PC has distinct histopathological characteristics and its incidence has increased over the past
decades.
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Introduction
Parathyroid carcinoma (PC) is a rare cause of primary hyper-
parathyroidism (PHPT) [1], found in approximately 1% of PHPT
cases and the least common endocrine cancer worldwide [2–5].
Recent reports indicate increasing incidence of PC in the United
States in 1988 to 2003 [6]), and in Australia in 2000–2010 com-
pared to 1991–2000 [7]. Diagnosis of PC is challenging.
Although patients suffering from PC usually present with higher
serum calcium and parathyroid hormone (PTH) concentrations
compared to those with adenomas, there are no preoperative
markers for PC. The diagnostic WHO criteria for PC are meta-
static disease, or vascular, perineural or capsular tumor inva-
sion [8]. The lack of resection margins sometimes makes the
task of the pathologist impossible [5,9]. PC is regarded as a
rather aggressive disease, with recurrence rates of 40–60%
[9,10], and a median overall survival of 14.3 years [10]. Atypical
adenomas (APA) are borderline parathyroid tumors sharing
similar histological features with PC but lacking evident invasion
and metastasis [8]. Morphology of APA and PC include diffuse
growth pattern, fibrous septa, necrosis, high mitotic activity as
well as negative parafibromin stain and increased Ki67 prolifer-
ation index (PI) [11–13]. Parafibromin is often absent or reduced
in PC, and this protein is encoded by the CDC73 gene, which
may be mutated in up to 70% of sporadic PCs [14–18].
The only potential cure for PC is radical surgery with suffi-
cient margins (en bloc resection) [4,10,19,20]. Surgery, when
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possible, is first-line treatment also for recurrent disease [21].
Because the disease is so rare, there are no randomized, con-
trolled trials.
Most studies on PC are register-based, lacking combined
and detailed clinical and histological data [22–24]. To
improve the understanding of this rare disease, we per-
formed a nationwide study on PC in Finland. We here pre-
sent clinical and histopathological data and outcome of PC
compared to APA and PA in Finland, and report on the inci-




This retrospective nationwide study comprises clinical data
and tissue specimen from all patients diagnosed with para-
thyroid cancer (PC; n¼ 32) in Finland during 2000–2011.
These patients were identified from the Finnish Cancer
Registry, the database of the Department of Pathology
(Huslab and University of Helsinki, Finland) and the hospital
databases of the five Finnish University Hospitals and eight
Finnish Central hospitals using the ICD-10 code (C75.0). One
patient had a previously identified deletion in the CDC73
gene [25]. The PC group was compared to all atypical para-
thyroid adenoma (APA; n¼ 28) cases diagnosed during
2000–2011 that were found in the Helsinki pathology data-
base. The third subgroup consisted of 72 operated parathy-
roid adenoma patients (PA), matched for age and gender
regards the PC group, also retrieved from the Helsinki path-
ology database. None of the patients had MEN-1.
Re-evaluation
The diagnosis of PC was confirmed by re-evaluation of the
primary tumors (J.A. and E.R.). PCs were confirmed to have
either unequivocal invasion (capsular, perineural or vascular)
and/or distant, regional, or lymph node metastasis, according
to the 2004 WHO classification [8]. Seven of 39 patients ori-
ginally classified as PC were excluded from the study: three
because PC could not be confirmed, and four because they
were re-classified as APA.
Data collection
Histological, clinical and surgical and follow-up data including
reoperations and other given treatments were collected.
Laboratory data was available from the time of preoperative
evaluation until end of each patient’s follow-up. Primary sur-
gery was considered successful if, on the first postoperative
day, serum PTH had decreased by 50%, and serum ionized
calcium was below the upper limit of the reference range (in
cases with severe hypercalcemia within one month). The
operations were classified as local resection (removal of the
tumor following the peritumoral capsule), or en bloc/radical
resection (consisting in minimum of parathyroidectomy with
removal of the ipsilateral thyroid lobe and, in some cases,
adjacent structures or lymph nodes). The diagnosis of
recurrent PC was based on increased serum ionized calcium
and PTH concentrations and surgical findings implicating PC
confirmed by histopathology. In 2016, CDC73 mutation ana-
lysis was offered to all PC and APA patients not previously
screened. Altogether 56% of the PC and 57% of the APA
patients were investigated.
Incidence and survival
Patients were followed until death or the last follow-up date
(30 August 2015). Survival data, causes of death and the
population data during the years 1955–2013 in Finland were
obtained from Statistics Finland (www.statistics.fi). The
nationwide number of PC cases during 1955–2000 were
retrieved from the Finnish Cancer Registry.
Laboratory assays and localization studies
All laboratory tests were performed using in-house methods
at the laboratories of each hospital. Serum ionized calcium
(Ca-ion) was measured by ion-specific electrodes (normal
range 1.15–1.30mmol/l), and serum PTH by a chemilumino-
metric assays (normal range 15–65 ng/l). Serum 25-hydroxyvi-
tamin D (25OHD, normal range>50 nmol/l) was measured by
high-performance liquid chromatography (HPLC), serum cre-
atinine (normal range 50–90 lmol/l for women; 60–100 lmol/
l for men) by enzymatic photometric assay, and serum alka-
line phosphatase (normal range 35–105 IU/l) and serum phos-
phate (normal range 0.76–1.41mmol/l for women,
0.71–1.53mmol/l for men) by photometric methods.
All study subjects underwent preoperative tumor localiza-
tion studies including ultrasound and dual-phase scintigraphy
with 99Technetium-sestamibi alone or in combination with
123Iodide. Some patients underwent additional imaging with
computer tomography or magnetic resonance imaging. The
imaging result was considered accurate if it represented a
true positive finding, as confirmed by surgery and histopath-
ology, without false negative or false positive findings.
Targeted next generation sequencing and multiplex
ligation-dependent probe amplification analysis of the
CDC73 gene
Genomic DNA was isolated from peripheral blood samples
using standard methods for the detection of germline muta-
tions. Haloplex Target Enrichment System (Agilent
Technologies, Santa Clara, CA, USA) was used to capture the
17 exons of the CDC73 gene for next generation sequencing.
Online design tool SureDesign (https://earray.cham.agilent.
com/suredesign/) was used for capturing the probe design.
Target regions consisted of exons, UTRs and 10bp flanking
regions of the CDC73 gene from the RefSeq database
(GRCh37/hg19). Total length of the target region was 133 kb
of genomic DNA on chromosome 1q31.2. Library preparation
was performed using HaloPlex Target Enrichment Kit follow-
ing the manufacturer’s instructions. Paired-end sequencing
(2300 bp) was performed on MiSeq instrument (Illumina, San
Diego, CA, USA) using the MiSeq Reagent Kits v3 (600 cycles).
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Data analysis and variant calling was performed as previously
described [26]. An MLPA kit P466-A1 CDC73 (MRC Holland,
Amsterdam, Netherlands) was used for detection of deletions
and duplications of one or more exons according to the
manufacturer’s instructions.
Histological studies and preparation of tissue
microarrays
Formalin-fixed and paraffin-embedded tissue samples of the
primary operations were retrieved for all patients and reex-
amined. The following histological features were evaluated
(J.A. and E.R.): (1) dominant cell type, (2) growth pattern, (3)
fibrous bands, (4) cystic changes, (5) hemosiderin deposits, (6)
necrosis, (7) mitotic count per 10 high-power fields (HPF), (8)
pathological (¼ atypical) mitoses, (9) nuclear atypia, (10) vas-
cular, (11) capsular and (12) neural invasion. The cut-off for
increased number of mitoses is >0 per every 10 cells counted
and srong mitotic activity is >1 per every 10 cells counted.
Two patients (one PC patient and one APA patient) could
not be included in the constructed tissue microarray (TMA)
as there was not sufficient tissue material left. For construc-
tion of TMA blocks, we selected the histopathologically most
representative areas of the tumor specimen. For PC and APA,
six cores were sampled from the tumor block with 1.0mm
punchers by a semiautomatic tissue microarrayer (Beecher
Instruments, Silver Spring, MD, USA; MTABoosterVR Version
1.01 for Beecher Manual Arrayer, Alphelys, Plaisir, France),
and inserted into a recipient paraffin block. The correspond-
ing number for benign adenomas (PA) was three cores.
Immunohistochemistry
The TMA blocks were cut into 4-lm sections, and processed
through deparaffinization in xylene and rehydration with
graded alcohol series. The MIB-1 slides for calculation of Ki67
indices were treated in a pretreatment (PT) module (DAKO
PT Link) in Tris-HCl buffer (pH 8.5) for 20min at 98 C and
the parafibromin slides were pretreated with Tris-EDTA in the
PT module. Immunostainings were performed in an
Autostainer 480 (LabVision Thermo Scientific, UK Ltd,
Cheshire, UK). The MIB-1 and parafibromin slides were incu-
bated in 0.3% Dako REAL Peroxidase-Blocking Solution (Dako,
S2023) for 5min to block endogenous peroxidase. The MIB-1
(Dako, Santa Clara, CA, USA, M7240, Clone MIB-1) primary
antibody was used in a dilution 1:100 for one hour incuba-
tion and the parafibromin (Santa Cruz Technologies, Dallas,
TX, USA, sc-33638, Clone 2H1) antibody immunohistochemis-
try was done in a dilution of 1:300 for 30min incubation.
Thereafter, followed by 30min incubation with Dako REAL
EnVision/HRP detection system, Rabbit/Mouse (ENV) reagent
(Dako, K5007), the visualization of staining was done by Dako
REAL DABþChromogen (Dako, K5007) for 10min. Washing
with PBS-0.04%-Tween20 took place between each step. PTH
immunochemistry was done in fully automated instrument,
Ventana Benchmark XT. As a pretreatment buffer was used
CC1 for 60min. PTH (Novocastra, Buffalo Grove, IL, USA, NCL-
PTH-448, Clone 105G7) was diluted into 1:100 and incubated
for 30min. Detection kit was UltraView DAB (Ventana,
Tuscon, AZ, USA, 760-500). All the three stainings were coun-
terstained with Mayer’s hematoxylin and mounted in mount-
ing medium. Parathyroid tissue was used as a positive
control for PTH. A parathyroid carcinoma was used as nega-
tive control for parafibromin, and a parathyroid adenomas as
a positive control.
Scoring of immunohistochemistry
The Ki67 proliferation index by MIB-1 staining was
assessed by the Immunoratio-program as described by
Tuominen et al. [27]. The area with the highest MIB count
was chosen for Immunoratio imaging (Magnification 400).
The results were analyzed by a pathologist (H.L.) blinded to
the clinical data.
Scoring of parafibromin and PTH was done independ-
ently by two researchers (H.L. and E.R.), without knowledge
of the clinical data. In case of disagreement, a consensus was
done (kappa 0.90 for parafibromin, and 1.00 for PTH). The
parafibromin staining was considered positive (2) if >95% of
the nuclei of the neoplastic cells in the TMA spot were posi-
tive, and negative (0) if >99% of all these nuclei were nega-
tive [28]. Counts between these cut-offs were considered as
weak positives (1). Cytoplasmic staining for parafibromin was
considered nonspecific and disregarded. For the PTH stain,
negative was denoted 0, and positive 1.
Ethics
The study was approved by the institutional review board of
Helsinki University Hospital. The study protocol was also
approved by the ethics committees of the four other Finnish
University Hospitals, by the National Supervisory Authority
for Welfare and Health in Finland, and by the National
Institute for Health and Welfare in Finland.
Statistical analysis
Statistical analysis was performed with SAS for Windows,
Version 9.3 (SAS Institute, Cary, NC, USA). Absolute numbers
and percentages were used to describe categorical data, age
and follow-up time were presented in median and range. All
other continuous data did not follow normal distribution,
and were presented in medians and IQR. In the tables, num-
ber of patients is given if the information is lacking for more
than 5% of the group. We assessed statistical significance
between the three subgroups with Fisher’s exact test for cat-
egorical variables and with Kruskal–Wallis test for continuous
variables. Correlation between immunohistochemical results
of the original samples and those of TMA were evaluated by
calculating Pearson’s correlation coefficient. Survival analysis
was calculated with the Kaplan–Meier method. The change
in the incidence of PC was assessed with chi square-test,
where number of new PC cases were compared to the
respective average adult population in Finland over the spe-
cific time periods (1955–2013). All incidence rates are
reported as average annual incidences per 10,000,000
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population, calculated over 5-year-period (except years
2010–2013 over a 4-year period). The level of significance
was chosen as p value less than .05 (two-tailed).
Results
Characteristics of the study cohort
Characteristics of the study cohort are given in Table 1.
There were 32 patients with PC, with 18 (56%) females and
14 (44%) males. Median age at diagnosis was 61 (17–83), 59
(31–84) and 62 (15–83) years for the PC, APA and PA sub-
groups, respectively (Table 1). The median age of women
and men in the PC group was 68 (48–84) and 54 (17–76)
years, respectively. The median follow-up time (FU) of the PC
group was 6.7 (range 2.0–13.9) years. Of the PC patients, 12
(37.5%) had an additional benign parathyroid adenoma or
atypical adenoma in their medical history or during follow-
up, compared to one in the APA group (p¼ .002).
Biochemical characteristics and disease manifestations
Biochemical characteristics and disease manifestations are
presented in Table 1. There were no nonfunctioning tumors.
At the time of diagnosis, Ca-ion, PTH and creatinine concen-
trations differed significantly between PC, APA and PA sub-
groups (Table 1). The highest Ca-ion and PTH concentration
in the APA and the PA groups were 2.05mmol/l and
2769 ng/l, and 1.77mmol/l and 1887 ng/l, respectively. The
lowest corresponding values in PC were 1.38mmol/l and
68 ng/l (Figure 1). Preoperative hospitalization because of
marked hypercalcemia or hypercalcemic crisis (Ca-ion
>1.75mmol/l) was needed for 44, 22 and 3% of PC, APA and
PA subgroups, respectively (p< .001). The prevalence of renal
(renal failure, kidney stones) and bone (pathological fractures,
osteoporosis, Brown tumors) manifestations differed signifi-
cantly between the subgroups (p¼ .010 and p¼ .002,
respectively) (Table 1).
Preoperative localization studies
Preoperative ultrasound imaging was accurate in 77, 43 and
39% of PC (n¼ 26), APA (n¼ 23) and PA (n¼ 64) subgroups,
respectively (p< .001). Planar isotope imaging was accurate
in 77, 64 and 70% of PC (n¼ 26), APA (n¼ 25) and PA
(n¼ 68) subgroups, respectively (p ¼ .62).
Surgery
Of the PC, APA and PA subgroups, 91, 93 and 91% were
cured by primary surgery; the postoperative status of one
APA patient remains unknown. Of the PC, APA and PA sub-
groups, 53, 82 and 92%, respectively (p< .001), underwent
local resection. The corresponding figures for en bloc or rad-
ical resection were 47, 18 and 8%, respectively (p< .001). The
corresponding numbers for tumor weight and size were 4.8
(2.8–14.0) g, 2.6 (1.3–4.5) g and 0.76 (0.43–1.5) g, (p< .001);
and 2.95 (2.0–3.0) cm, 2.0 (1.4–3.0) cm and 1.6 (1.2–2.0) cm
(p< .001), respectively. At primary surgery, additional patho-
logical parathyroid glands (n¼ 8) were identified in PC (n¼ 5)
only. The histopathological diagnoses were as follows: PC
(n¼ 1, on the contralateral side of the neck), APA (n¼ 1), PA
(n¼ 5) and hyperplasia (n¼ 1). In PC, tumor invasion to the
thyroid gland, to the surrounding muscle tissue and to the
trachea was detected in one, one, and one patient, respect-
ively. Two patients had lymph node metastases.
Histological findings
Histological findings are presented in Table 2 and in Figure 2.
Invasion
Capsular, vascular and perineural invasion was present in 72,
72 and 9% of the PC specimens. By definition, there was no
invasion in the APA and PA subgroups.
Mitotic activity
Increased mitotic activity (>0 cells per 10 cells counted) char-
acterized PC compared to APA and PA (25, 9 and 1%,
respectively, p< .001). Mitotic activity was particularly strong
(observed in >1/10 cells) in 2 of 32 PC and 1 of 28 APA
samples.
Cell type
Chief cells (100%) was the dominant cell type in PC and APA
compared to PA (69, 68 and 41%, respectively, p< .001),
while oncocytic cells were more common in APA and
PA compared to PC (16, 20 and 9%, respectively, p¼ .079,
Table 2).
Growth pattern
There were significant differences in the growth patterns
between the subgroups. Diffuse growth pattern was more
common in PC compared to APA and PA (overall distribution;
p< .001, Table 2), while follicular growth pattern was more
common in A and APA compared to PC (overall distribution;
p< .007), with no clear differences in cystic or islet-cell
growth patterns between the subgroups (Table 2).
Necrosis, hemosiderin deposits, fibrous bands and cysts
There were significant differences in the distribution patterns
of all the aforementioned parameters (Table 2). Necrosis was
present in PC (3 of 32) only (p< .05). Hemosiderin deposits
and fibrous septae were more common in PC and APA com-
pared to PA (56, 61 and 1%, p< .001; and 88, 93 and 3%,
p< .001), respectively (Table 2). Cysts were most common in
PA (53%) compared to APA (44%) and PC (31%) (overall dis-
tribution, p< .05).
Immunohistochemistry
Immunohistochemical data are presented in Table 3 and
Figure 3. PTH stain was positive in all samples (100%). In PC,







































































































































































































































































































































































































































































































































































































































































































































































































































































































































APA and PA subgroups, parafibromin stain was positive (>95%
of cell nuclei stained) in 22, 33 and 76% of cases, respectively
(p< .001) (Table 3). The corresponding percentages for nega-
tive parafibromin stain were 13, 4 and 0%, respectively.
Ki-67 indices analyzed by Immunoratio (TMA) were signifi-
cantly higher in PC and APA compared to PA (2.7% vs. 2.0%
vs. 0.9%, p< .001) (Table 3). Ki-67 percentages of the original
samples (PC 5.0%, APA 2.0%), correlated with those of the
TMA (r¼ 0.42, p¼ .03; and r¼ 0.72, p< .001, respectively).
CDC73 mutation analysis
The CDC73 germline mutation status for PC and APA, in
relation to parafibromin stain, are given in Table 3. One
18-year-old man with PC, with negative parafibromin stain,
had a deletion of exons 1 to 10 (25). One 31-year-old man
with APA, with recurrent disease, kidney stones and weak
positive parafibromin stain had a p.Arg92 Term mutation in
codon 91.
Recurrences and cancer deaths
In PC, 6/29 patients (21%) cured by primary surgery recurred
after a median of 24 months (range 4–60), with Ca-ion and
PTH concentrations of 1.41mmol/l (range 1.20–1.60) and
152 ng/l (range 101–1241), respectively (Table 4). One patient
with chronic hypocalcemia due to severe chronic renal failure
was normocalcemic (1.20mmol/l) at recurrence. In three PC
patients, PHPT recurred as an adenoma. In APA, one patient
had persistent disease due to tumor rupture. In another APA
patient, re-operation for persistent disease revealed PC.
A third APA patient, cured by primary surgery, recurred in 23
08:31  Wednesday, November 16, 2016 1


















Figure 1. Distribution of preoperative serum ionized calcium and parathyroid hormone concentrations in subgroups of parathyroid carcinoma (1), atypical adenoma
(2) and benign adenoma (3).
Table 2. Histopathological findings in the different subgroups.
Parathyroid carcinoma (n¼ 32) Atypical adenoma (n¼ 28) Adenoma (n¼ 72) p Value
Proliferation Mitotic activity








Pathological mitoses 2 (6%) 1 (5%) 0 .086
Nuclear atypia 14 (44%) 5 (18%) 8 (11%) .003










Clear cytoplasmic 50% 1 (3%) 0 4 (5%) .951
Oncosytic 50% 3 (9%) 5 (16%) 14 (20%) .079






















Cystic 50% 1 (3%) 2 (7%) 6 (8%) .844
Islet-cell 50% 8 (25%) 6 (19%) 28 (38%) .301
Necrosis 3 (9%) 0 0 .024
Fibrous septae 28 (88%) 25 (93%) 2 (3%) <.001
Hemosiderin deposits 18 (56%) 17 (61%) 1 (1%) <.001
Cysts 10 (31%) 14 (44%) 17 (53%) .037
p Values <.05 are considered statistically significant (marked in bold).
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months because of another APA, located in the same site as
the primary tumor. In the PA group, one patient recurred,
due to an adenoma.
Overall 5- and 10-year survivals in PC were 91 and 72%,
respectively, and did not differ significantly from the other sub-
groups (Figure 4). In PC, 4 of 32 patients (12.5%) died of dis-
ease at a median FU of 43.9 (range 23.4–61.3) months (Table
4). Four other deaths in the PC group were due to severe
asthma, stroke, Merkel cell carcinoma and salivary gland
carcinoma, respectively. In APA, all deaths occurred in cured
patients and were unrelated to PHPT.
Treatments and treatment complications in parathyroid
carcinoma
PC patients underwent on average 1.7 (range 1–5) operations
for the disease (Table 4). Sixty-nine percent received calcium
Table 3. Parafibromin and Ki-67 proliferation indices and germ-line CDC73 mutation status in the different subgroups.
Parathyroid carcinoma (n¼ 32) Atypical adenoma (n¼ 27) Adenoma (n¼ 71) p Value
PARAFIBROMIN STAIN
Positive 7 (22%) 9 (33%) 54 (76%) <.001a, .34b
Weak positive 21 (66%) 17 (63%) 17 (24%)
Negative 4 (13%) 1 (4%) 0 (0%)
GERM-LINE CDC73 GENE MUTATION POSITIVE
Parafibromin positive 0% (4/7) 0% (4/9)
Parafibromin weak positive 0% (12/21) 10% (10/17)
Parafibromin negative 50% (2/4) 0% (1/1)
KI-67 INDICESc
Ki-67 (TMA) 2.7% (0.4–15.6) 2.0% (0.3–7.5) 0.9% (0.2–4.7) <.001a, .23b
Ki-67 (original specimen) 5.0% (1–40) 2.0% (1–10) 0.17b
Immunohistochemical results were obtained from the tissue micro array.
CDC73 gene mutation analysis was available for 18/32 (56%) and 16/28 (57%) of the patients with PC and APA, respectively. Percentages of CDC73 mutation
positive patients are presented with proportions of patients who underwent mutation analyses in brackets.
The tissue sample of one APA patient with CDC73 gene analysis was not sufficient for TMA technique. The patient is excluded from this table.
afor comparison of three subgroups, for PC vs. PA, and for APA vs. PA.
b for comparison of PC vs. APA.
cMedian and range.





Figure 2. Diagnostic (A–B) and typical (C–F) findings in parathyroid carcinoma. A: Infiltrative growth to adipose tissue, B: Vascular invasion, C: Diffuse growth pat-





Figure 3. Parafibromin stain in parathyroid carcinomas (A negative and B positive). Digital images of Ki-67 staining in Tissue Micro Array in a parathyroid adenoma
with a low PI (C) and in an aggressive parathyroid carcinoma with high PI (D). The corresponding pseudocolor image of Immunoratio-program respectively with
low PI (E) and high PI (F).
Table 4. Recurrences, treatments and survival in the different subgroups.
Parathyroid carcinoma (n¼ 32) Atypical adenoma (n¼ 28) Adenoma (n¼ 72) p Value
Persistent diseases 3 2 0
Recurrences 6 (21%) 1 1
Median time to recurrence (months, range) 24 (4–60) 23 18
Total number of operations for PHPT (mean and range) 2 (1–5) 1 (1–4) 1 (1–3) <.001
2 operations 47% 22% 6%
Metastasis during follow-up time 5 (neck lymph nodes, lungs, bone) 0 0
TREATMENTS
Calcium decreasing medication 22 (69%) 5 (19%) 4 (6%) <.001
Radiation therapy 7 (22%) 0 0 <.001
Chemotherapy 4 (13%) 0 0 <.001
COMPLICATIONS (TOTAL)
Laryngeal nerve palsy 11 (34%) 3 (11%) 3 (4%) <.001
Transient unilateral 4 0 1
Persistent unilateral 7 2 2
Persistent bilateral 0 1 0
Hypoparathyroidism 18 (56%) 5 (18%) 1 (1%) <.001
Temporary, prolonged 11 (34%) 4 (15%) 1 (1%)
Persistent 7 (22%) 1 (4%) 0
SURVIVAL
Deaths during follow-up 8 6 8 .79
Disease-related deaths 4 (13%) 0 0
Overall 5-year survival 91% 84% 92% NS
Overall 10-year survival 72% 73% 83% NS
Pre- and postoperatively.
p Values <.05 are considered statistically significant (marked in bold).
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decreasing agents (zoledronic acid or cinacalcet), either for
severe preoperative hypercalcemia or for PC not cured by
surgery (p< .001 compared to APA and PA). Of the PC
patients, 22 and 13% were treated with external neck radi-
ation therapy and/or chemotherapy (temozolomide), respect-
ively (Table 4). Seven patients (Table 4) underwent radiation
therapy, four after primary surgery and three after re-oper-
ation because of recurrence. Of the four patients who under-
went radiation therapy after primary surgery, three died
within four years, and one has not recurred during 11 years
of follow-up.
Treatment complications caused by all operations during
follow-up are shown in Table 4. The prevalence of transient
or persistent hypocalcemia in PC, APA and PA were 56, 11
and 4%, respectively (p< .001), and for transient or persistent
laryngeal nerve palsy 34, 11 and 3%, respectively (p< .001).
In PC patients, preoperatively increased creatinine concentra-
tions did not improve after surgery (p¼ .39) (Table 1).
Factors associated with recurrence or cancer death
Characteristics of PC patients with and without recurrence
are presented in Table 5. Distant metastases were found in 5
out of 6 patients with recurrent PC, and four of them died of
disease (Table 5). Median preoperative Ca-ion concentrations
were slightly higher in recurrent compared to cured PC, but
the difference was not statistically significant (Table 5).
Median preoperative PTH concentrations did not differ sig-
nificantly, but the lowest PTH concentration at diagnosis in
recurrent PC was 358 ng/l, compared to 68 ng/l in the cured
PC group (Table 5). Median tumor size was similar (Table 5).
Recurrent PC was more often characterized by lymph node
metastases compared to the cured PC group (p¼ .03, Table
5). Parafibromin expression was weaker in recurrent com-
pared to cured PC. All of the six PC tumors that recurred
were characterized by vascular invasion at primary diagnosis,
and all tumors characterized by necrosis (n¼ 3) recurred
(Table 5). Recurrent PC had significantly higher mitotic activ-
ity, number of pathological mitoses, and more marked
nuclear atypia (p< .05, p< .03 and p< .03, respectively;
Table 5).
Incidence of parathyroid carcinoma
Figure 5 illustrates the increasing incidence of PC. In the
years 1955 to 2000, the mean incidence was 1.42
cases/10,000,000/year (range 0.52–2.14). During 2000 to 2013,
the mean incidence was 7.14 (range 3.42–10.38) rising from
3.4 (2000–2004) to 10.4 (2010–2013), p< .001 (Figure 5).
Discussion
To the best of our knowledge, this is the first study presenting
a nationwide cohort on PC. As the series does not include only
the most aggressive cases, it can be regarded as unbiased. The
present study is one of the largest studies on PC, including 32
cases and with detailed clinical and histological comparison to
the two other parathyroid tumor subgroups, APA and PA. All
tumor samples were reexamined, which resulted in re-classifi-
cation of 7 of originally 39 PC cases.
We demonstrate a significant increase in the incidence of
PC in Finland during the last 20 years compared to the time
period 1955–2000. Previous studies from the United States
[6] and from Australia, reported a similar increase in disease
rate in years 2000–2010 compared to the previous decade
[7]. The increasing incidence of PC may partly be explained
by improvements in the diagnostic accuracy, but may also
reflect a true rise.
In this study, median age at diagnosis of PC was 60.8
years. Close to half (44%) of these patients were male in





















Figure 4. Survival analysis in parathyroid carcinoma, atypical adenoma and parathyroid adenoma. 5-year and 10-year survivals are 90.6 and 71.9% for PC, 83.9 and
73.4% for APA, and 91.7 and 82.5% for PA (p ¼ NS).
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contrast to the distribution in benign PHPT (2–3 times more
common in women), in line with previous data [9,22,29]. The
reason for this difference in sex distribution is unclear. At the
time of diagnosis, Ca-ion, PTH and creatinine concentrations
differed significantly between PC, APA and PA subgroups,
with the highest concentrations observed in PC (all p< .001).
In PA, PTH and Ca-ion concentrations did not exceed
1887 ng/l and 1.77mmol/l, respectively (Figure 1). According
to our study, hospitalization for severe hypercalcemia as well
as kidney and bone manifestations are more common in PC
compared to APA and PA (all p< .001). In line with previous
studies [10,12], postoperative hypocalcemia was significantly
more common in PC compared to both APA and PA
(p< .001). Of note, the preoperative mean creatinine concen-
tration was increased in the PC group and did not return to
normal after surgery.
There is little previous data on preoperative localization in
PC [21]. In the present study, ultrasound more accurately
identified PC tumors compared to APA and PA. PCs were
also larger and heavier (p< .001), as previously described
[12]. PC was characterized by multiglandular disease, as 35%
had an additional, benign parathyroid tumor, in line with
previous reports [10].
Diffuse growth pattern characterized by chief cells is typ-
ical for PC, but may also be seen in other parathyroid tumor
subgroups. We observed that higher mitotic activity and
nuclear atypia were more common in PC, as previously
reported [12]. Global loss of parafibromin predicts poor out-
come in PC [30], but negative parafibromin alone cannot dis-
tinguish PC from APA [12,31]. In the present study,
significant differences in parafibromin stain between the sub-
groups were observed (p< .001). Although parafibromin stain
was weaker in PC, a completely negative stain was observed
in only 13% of PC, compared to 4% of APA and 0% of PA,
respectively. The proportion of PAs demonstrating relatively
weak positive parafibromin stain in the present study was
24%, which might be related to differences in the staining
process compared to other studies [17].
None of the PCs that did not recur stained negative for
parafibromin. One-third of the recurrent PCs were completely
negative for parafibromin and none clearly positive. The
patient with APA and a negative parafibromin stain had per-
sistent disease and underwent reoperations.
Germ-line CDC73 mutation analysis was available for
56 and 57% of the PC and APA subgroups, respectively.
One young man with early-onset PC and familial disease
had a CDC73 mutation [25], with a total mutation rate of
6% in this national Finnish PC cohort. In addition, a 31-
year-old man with APA, recurrent disease and kidney
stones had a p.Arg92 Term mutation in codon 91. The
percentage of CDC73 mutations in the APA group was
also 6%. Others have reported that 15% to 70% of spor-
adic PC cases may demonstrate somatic or germline
CDC73 mutations [20]. A limitation of the present study is
that germ-line CDC73 mutation analysis was not available
for all PC and APA patients and somatic CDC73 mutation
screening was not performed. However, Cetani et al. [16]
demonstrated that, compared to mutation analysis, nega-
tive parafibromin stain better predicts poor outcome in
PC, and that the added value of CDC73 mutation analysis
is identification of germline mutations, that prompts
screening of family members. Negative parafibromin stain
seems to predict aggressive behavior both in APA and in
PC [32,33].
A proliferation index >5% in a parathyroid tumor is sug-
gestive of parathyroid carcinoma [34–39]. In our study,
median Ki67 differed significantly between the subgroups
with higher percentages in PC, but there was considerable
overlapping. All benign adenomas in the present study had






































Figure 5. Incidence of parathyroid carcinoma in Finland (per 10,000,000/year).
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hot spots cannot be analyzed, as the method analyses three
to six spots of each tissue sample. Consequently, the prolif-
eration index in TMA is lower although it correlates well
with that originally obtained. In contrast to the present and
previous smaller series [31,37,40], Quinn et al. [12] reported
that neither Ki67 nor parafibromin stain differed between
PC and APA. However, as original pathology reports were
used in that study, without reexamining the samples, the
results may have been hampered by interobserver
variability.
In the present study, half (53%) of the surgical procedures
for PC were local resections, a figure close to that of the
NCDB reports [24]. Three patients with PC had incomplete
tumor removal. During a median follow-up of 6.7 years, PC
recurred in 21% of the patients, in line with the report of
23% recurrence after 55 months of follow-up by Villar del
Moral et al. [29]. Others report of persistent or recurrent dis-
ease in over 50% PC patients [10,21,41]. Talat et al. [9]
reported a recurrence rate of 63% during 6.1 years, after
exclusion of subjects characterized by capsular invasion only.
Mean time of recurrence in previous reports range from 2.5
to 8.4 years. However, late recurrences (23 years after primary
surgery) have been reported [10,21,23]. In the present study,
time to recurrence was 2 years. It is possible that there will
be later recurrences of the present cohort after longer fol-
low-up.
Five of the 32 PC patients developed metastatic disease
and, despite all treatments, 4 (80%) of them died of disease
during the 6.7-year FU. The overall 5-year-survival rate, 91%,
is in line with others [29], but seems slightly better than
Table 5. Clinical, biochemical and histological findings in patients with recurrent vs cured parathyroid carcinoma (PC).
PC with recurrence (n¼ 6)
PC cured in the primary operation,
no recurrences (n¼ 23) P - value
Age (median) 61 (45 - 68) 65 (17 – 84) .89
Male 3 50% 11 48 % 1.00
Ca-ion, mmol/l 1.86 (1.61 – 2.42) 1.72 (1.55 – 1.97) .20
PTH, ng/l 1030 (358- 2120) 904 (68 – 2220) .41
Creatinine, lmol/l 119 (68-163) 106 (58 – 430) .30
Alcaline phosphatase, IU/l 134 (119-256) 70 (24 – 651) .27
Palpable tumour 2 33 % 6 26 % 1.00
Hypercalcaemic crisis 3 50 % 10 43 % 1.00
Renal manifestation 5 83 % 9 39 % .08
Bone manifestation 3 50% 10 43 % .64
Tumor size (cm) 3.0 (0.5 – 3.5) 2.9 (1 – 5) .46
Metastasis
Local 2 (trachea, muscle) 1 (thyroid) .09
Lymph nodes 2 (cervical) 0 .03
Primary surgery
Local resection 3# 50 % 13# 57 % 1.00
En bloc or radical
resection 3 50 % 10 43 %
Invasion
Capsular 5 83 % 16 70 % .64
Vascular 6 100 % 17 74 % .29
Perineural 2 33 % 1 4 % .10
Proliferation
Mitotic activity: 3 50 % 5 22 % .045
> 1/10 2 33 % 0
Pathological mitoses 2 33 % 0 .02
Nuclear atypia 5 83 % 5 22 % .02
strong 0 2
Dominant cell type
Chief cell 100 % 4 67 % 16 72 % 1.00
 50 % 6 100 % 19 87 % 1.00
Clear cytoplasmic 50 % 0 2 9 % 1.00
Oncocytic 50 % 1 17 % 3 9 % .19
Growth pattern
Diffuse 100 % 5 83 % 13 57 % .65
Follicular 50 % 0 2 9 % 1.00
Cystic 50 % 0 1 4 % 1.00
Islet-like 50 % 1 17 % 6 21 % .51
100% chief cells and 100 % diffuse 4 67 % 9 41 % .37
Necrosis 3 50 % 0 .006
Fibrous septae 5 83 % 20 87 % 1.00
Hemosiderin deposits 2 33 % 14 61 % .36
Cysts 1 17% 7 30 % .71
Immunohistochemical markers in TMA
Parafibromin median 0.5 1.0 .01
0 / 1 / 28 2 / 4 / 0 0 / 17 / 6
Ki-67 mean/median 8.2 / 7.9 3.1 / 2.3 .11
All continuous variables are presented as medians and range.at primary operation,
#1 patient with radical second operation.
8in parafibromin staining: 0 ¼ negative staining, 1¼ decreased staining, and 2 ¼ normal staining for parafibromin.
Normal ranges: Ca-ion 1.15-1.30mmol/l, PTH 15-65 ng/l, creatinine 60-100# , 50-90 $ lmol/l, alkaline phosphatase 35-105 IU/l.
P-values <.05 are considered statistically significant (marked in bold).
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previously reported 5-year overall survivals of 85%, derived
from various cancer databases and longitudinal retrospective
single institution reports [6,10,23,41,42]. These report 10-year
overall survivals between 49 and 77% [6,10,23,41,42]. In this
study, the disease-related and overall mortalities of PC
patients did not differ from those of APA or PA groups.
Advances in diagnostics and operative techniques may in
part explain the lower recurrence and mortality rates
reported in these more recent studies.
Characteristics of patients with recurrent PC (n¼ 6) com-
pared to cured PC were lymph node metastases at diagnosis,
development of distant metastases during FU, weaker parafi-
bromin stain and vascular invasion. Some [10,29] but not all
previous studies [6,23] reported an association between
recurrent PC and lymph node metastases. Vascular invasion
seems to predict aggressive behavior [9,43]. In addition, in
the present study, all tumors characterized by necrosis
recurred. As observed previously [29], recurrent PCs were
characterized by higher mitotic activity and pathological
mitoses, and more marked nuclear atypia (p< .05, p< .03
and p< .03, respectively). Parafibromin stain cannot be used
as a diagnostic marker of PC but a negative stain warrants
closer follow-up.
Conclusions
PC is characterized by a significantly worse clinical course
compared to APA and PA, including bone and renal manifes-
tations and hospitalization due to a severe hypercalcemia. PC
should be suspected preoperatively in all PHPT patients char-
acterized by Ca-ion concentrations 1.77mmol/l. However,
the lowest observed preoperative Ca-ion in PC was
1.38mmol/l. Histopathological characteristics of recurrent PC
include lymph node metastasis, vascular invasion, necrosis,
negative parafibromin stain and Ki67> 5%. The prevalence of
CDC73 germline mutations in Finnish patients with PC and
APA is approximately 6%. The incidence of PC has clearly
increased in Finland during the past decades.
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